Dosing considerations for rufinamide in patients with Lennox–Gastaut syndrome: Phase III trial results and real-world clinical data

Highlights • Rufinamide is an effective treatment option for Lennox–Gastaut syndrome. • Low starting doses and slow titration may improve rufinamide tolerability. • Clinical experience supports starting rufinamide at a dose of 5–10 mg/kg/day. • Real-world data show the dose can be escalated to 15–20...

Full description

Saved in:
Bibliographic Details
Published in:Seizure (London, England) England), 2017-04, Vol.47, p.25-33
Main Authors: Kothare, Sanjeev, Kluger, Gerhard, Sachdeo, Rajesh, Williams, Betsy, Olhaye, Omar, Perdomo, Carlos, Bibbiani, Francesco
Format: Article
Language:English
Subjects:
Adolescent
Adult
Anticonvulsants - administration & dosage
Anticonvulsants - adverse effects
Antiepileptic drug
Child
Child, Preschool
Clinical Trials, Phase III as Topic
Dose-Response Relationship, Drug
Dosing
Double-Blind Method
Drug Administration Schedule
Epilepsy
Humans
Lennox Gastaut Syndrome - drug therapy
Lennox–Gastaut syndrome
Neurology
Randomized Controlled Trials as Topic
Rufinamide
Treatment Outcome
Triazoles - administration & dosage
Triazoles - adverse effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Rufinamide is an effective treatment option for Lennox–Gastaut syndrome. • Low starting doses and slow titration may improve rufinamide tolerability. • Clinical experience supports starting rufinamide at a dose of 5–10 mg/kg/day. • Real-world data show the dose can be escalated to 15–20 mg/kg/day after 1–3 days. • The authors recommend not increasing rufinamide dose if no response is noted.
ISSN:1059-1311
1532-2688
DOI:10.1016/j.seizure.2017.02.008